Figure 5.

CC-885 Inhibits the Activation of PLK1 Substrates

(A) A549 CRBN^+/+ cells and CRBN^−/− cells were treated with 1 μM CC-885 for 24 h. Cells were then harvested and subjected to western blot with the indicated antibodies. Results are representative of three immunoblot analyses. (B) A549 cells were pretreated with 1 μM MLN4924 or 10 μM MG132 before the addition of 1 μM CC-885 for 24 h. Cells were then harvested and subjected to western blot with the indicated antibodies. Results are representative of three immunoblot analyses. Results are representative of three independent experiments. (C) A549 cells were treated with 50 nM volasertib, 50 nM CC-885, or both for 24 h. Cells were harvested and subjected to western blot with the indicated antibodies. Results are representative of three independent experiments.